Pembrolizumab and Total Skin Electron Beam Radiotherapy in Mycosis Fungoides and Sézary Syndrome
Status:
Withdrawn
Trial end date:
2024-07-24
Target enrollment:
Participant gender:
Summary
Hypothesis: Addition of low dose TSEBT to debulk MF/SS either before or during checkpoint
blockade with anti-PD-1 pembrolizumab monoclonal antibody therapy will be safe and well
tolerated.
Primary Objective:
• To determine the maximum tolerated dose (MTD) for the combination of total skin electron
beam therapy (TSEBT) and pembrolizumab regimen.
Secondary Objectives:
- To determine the preliminary efficacy of the combination of TSEBT with pembrolizumab.
- To determine the impact on patient-reported health-related quality of life outcomes.